Clinical trial NCT02401750: A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery
Official title: A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Capsules Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (b) for the Treatment of Adults With Moderate to Severe Pain Following Bunionectomy Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pain
Lead sponsor: Elite Laboratories, Inc
Sponsor class: INDUSTRY
First posted: 2015-03-30
Enrollment: 163
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study to evaluate the efficacy and safety of the administration of multiple doses of Oxycodone Hydrochloride plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride plus Naltrexone Hydrochloride (b) in patients who have undergone primary, unilateral, distal first metatarsal bunionectomy with osteotomy and internal fixation.

Detailed description: The study is designed to evaluate the safety and efficacy of oxycodone/naltrexone (a) and oxycodone/naltrexone (b) versus placebo. During the blinded phase of the study (inpatient portion) the dosing regimen is 1 capsule containing Oxycodone Hydrochloride plus Naltrexone Hydrochloride (a) or Oxycodone plus Naltrexone Hydrochloride (b) or placebo taken with 4 to 6 ounces (oz) of water every 6 hours (q6h) for 48 hours following the first dose (Multiple-dose Period) while in-house. Then for the open-label phase of the study (outpatient portion) dosing will occur every 4 to 6 hours prn with Oxycodone plus naltrexone. The active and placebo study medications will appear identical. Study subjects with acute postoperative pain of moderate to severe intensity following unilateral bunionectomy surgery will be randomized after surgery, and will stay at the study center for the duration of the 48-hour double-blind period after dose 1 of study medication. The study will be conducted in the following 4 periods: 1) a pre-treatment period, 2) a multiple-dose inpatient period (double-blind), 3) a multiple-dose outpatient period (open-label), and 4) End of Study/Follow-up.

Eligibility criteria: Inclusion Criteria:

1. Complete the informed consent process as documented by a signed informed consent form (ICF).
2. Be in generally good health and classified as either PS-1 or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
3. Be male or female, age 18 to 75 years, inclusively at the time of screening.
4. Be scheduled for a primary, unilateral, distal, first metatarsal bunionectomy with osteotomy and internal fixation (with no collateral procedures)
5. Female subjects are eligible only if all of the following apply:

   * Not pregnant (subjects of child-bearing potential must have a negative serum beta-human chorionic gonadotropin (B-hCG) pregnancy test at screening and a negative urine pregnancy test before surgery);
   * Not lactating;
   * Not planning to become pregnant within the duration of study;
   * Surgically sterile (bilateral tubal ligation or hysterectomy), or at least two years postmenopausal, or is practicing an acceptable form of birth control (defined as the use of an intrauterine device \[IUD\], a barrier method with spermicide, condoms, any form of hormonal contraceptives, partner with a vasectomy (surgery at least 6 weeks prior to start of surgery) or abstinence ) for at least 3 months prior to the screening visit and agrees to continue acceptable methods of contraception until one week following the last dose of ELI-200.
6. Be willing to complete the pain assessments and return to clinic as scheduled.
7. Subjects must experience postoperative pain (Day 1) that is at least moderate as measured by a NRS score ≥ 4 on a 0-10 NRS, less than 9 hours after discontinuing the nerve block.

Exclusion Criteria:

1. Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
2. Have a clinically significant abnormal electrocardiogram (ECG) at screening as determined by the Investigator.
3. Have had any type of gastric bypass surgery or have a gastric band. Have previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus.
4. Have a history of any medical condition or surgical procedure that would alter the absorption, distribution, metabolism or excretion of oxycodone or any opioid including but not limited to severe chronic diarrhea, chronic constipation, irritable bowel syndrome, or bowel resection.
5. Have a history of severe bronchial asthma, hypercarbia, or hypoxia (oxygen partial pressure \[PO2\] \<92%) or any respiratory condition that, in the opinion of the investigator, makes the subject unsuitable for the study. Mild episodic asthma or exercised induced asthma will be allowed.
6. Have, in the opinion of the investigator, a clinically significant abnormality on their clinical laboratory values (urinalysis, hematology and chemistry) at screening.
7. Have glycosylated hemoglobin (2c) \> 7%.
8. Have Addison's disease, benign prostatic hyperplasia, or kidney disease or other conditions as outlined in the Investigator's Brochure or the Percocet and Oxycontin Package Inserts that are contraindicated for use.
9. Have made a donation (standard donation amount or more) of blood or blood products (with the exception of plasma as noted below) within 56 days prior to Day -1 .
10. Have made a plasma donation within 7 days prior to Day -1.
11. Have a known allergy or hypersensitivity to any opioid analgesics, naltrexone, anesthetics (eg, propofol), acetaminophen, NSAIDs (eg, ibuprofen or naproxen, ketorolac) or any of the excipients
12. Have a known allergy or hypersensitivity to ropivacaine, Mepivacaine, Lidocaine or any related drug.
13. Have a history of significant intolerance (in the opinion of the investigator) or allergic hypersensitivity reaction to opioid use.
14. Not be willing to discontinue the prohibited medications, within the allotted time before surgery and throughout the duration of their participation in the study.
15. Have a history of substance(more than recreational use) or alcohol (more than 14 drinks in a week) abuse within 2 years before screening.
16. Have a positive drug screen or alcohol screen result.
17. Use of anti-coagulant agents (eg, Coumadin, heparin, etc)
18. Have a positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit.
19. Have an active malignancy of any type, or has been diagnosed with cancer within 5 years prior to screening (excluding squamous or basal cell carcinoma of the skin).
20. Have dysphagia and/or cannot swallow study medication whole.
21. Use concurrent therapy that could interfere with the evaluation of efficacy or safety parameters in the opinion of the investigator. (eg, any drugs, in the investigators opinion, that may exert significant analgesic properties or act synergistically with oxycodone, morphine, ketorolac, acetaminophen or ibuprofen).
22. Have a history of seizures or history of serious head injury.
23. Must not be a member of a vulnerable population as defined by the Code of Federal Regulations Title 45, Part 46, Section 46.111(b), including but not limited to employees (temporary, part-time, full-time, etc.) or a family member of the research staff conducting the study, or of the Sponsor, or of the Clinical Research Organization.
24. Have previously participated in a clinical trial using (Oxycodone Hydrochloride Naltrexone Hydrochloride, 1.5 mg or Oxycodone Hydrochloride , Naltrexone Hydrochloride 3.0 mg ).
25. Have a history of major mental illness that in the opinion of the Investigator may affect the ability of the subject to participate in the study. Institutionalized subjects will not be eligible for participation.
26. Been exposed to any investigational agent within 30 days or five half-lives (whichever is longer) prior to check-in for Day 1, Period 1, or is scheduled to receive an investigational device or drug (other than test product) during the course of this study.

Day -1 Exclusions:

1. Have taken any of the following drugs within the indicated times before surgery:

* over-the-counter or prescription non-steroidal anti-inflammatory drugs (NSAIDs) (such as ibuprofen \[Advil®, Motrin®\]), acetaminophen, or naproxen sodium (Anaprox®, Aleve®) within 24 hours; a daily dose of 81 mg of aspirin will be allowed (higher doses must be lowered to 81 mg a day by 72 hours prior to surgery).
* naproxen sodium sustained-release (Naprelan®) within 72 hours
* C-2 inhibitors (such as piroxicam or indomethacin) within 5 days
* oxycodone-containing drugs and other analgesic drugs containing opioids within the past 14 days
* immediate-release sedating antihistamines, tranquilizers, or hypnotics within at least 6 hours, or long-acting or sustained-released forms of these drugs within at least 7 days of Day -1

Day 1 Exclusion:

1. Have surgical complications (Day -1) that could compromise the safety of the subject or confound the results of the trial or any other reason that, in the opinion of the investigator, makes the subject unsuitable to participate.

Primary outcomes:
measure: Pain Intensity Measure for Oxycodone/Naltrexone (a)
timeFrame: Every 6 hours for 48 hours
Secondary outcomes:
measure: Pain Intensity Measure for Oxycodone/Naltrexone (b)
timeFrame: Every 6 hours for 48 hours
measure: Pain Relief Measure for Oxycodone/Naltrexone (a and b formulations)
timeFrame: Every 6 hours for 48 hours
measure: Number of Subjects with Changes in Physical Examination from Day 1 Pre-dose to End of Study
timeFrame: Pre-Dose Day 1 and Day 8
measure: Number of Subjects with Changes in Pulse Oximetry from Pre-Dose to post-dose time points
timeFrame: 48 hours (multiple time points) and at each out patient visit (Days 4, 6, 8)
measure: Number of Subjects with Changes in Blood Chemistry Analytes from baseline to end of study
timeFrame: Screening, 48 hours post-dose and Day 8
measure: Number of Subjects with Changes in Hematology Analytes from baseline to end of study
timeFrame: Screening, 48 hours post-dose and Day 8
measure: Number of Subjects with Changes in Urinalysis from baseline to end of study
timeFrame: Screening, 48 hours post-dose and Day 8
measure: Number of Subjects with Changes in Systolic Blood Pressure from baseline through multiple post-dose time points
timeFrame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8
measure: Number of Subjects with Changes in Diastolic Blood Pressure from Baseline through multiple time points post-dose
timeFrame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8
measure: Number of Subjects with Changes in Pulse Rate
timeFrame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8
measure: Number of Subjects with Changes in Respiratory Rate
timeFrame: Pre-Dose Day 1 through Day 3, Day 4, 6, 8
measure: Number of subjects with Adverse Events as a measure of Safety and Tolerability
timeFrame: Day 1 through 7 days post last dose
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Premier Research
state: Arizona
city: Pasadena
country: United States
facility: Chesapeake Research Group
state: Maryland
city: Austin
country: United States
facility: Premier Research
state: Texas
city: San Antonio
country: United States
facility: Endeavor Clinial Trials
state: Texas
city: Salt Lake City
country: United States
facility: Jean Brown Research
state: Utah
Study officials:
References: